Samarth Kulkarni - Aug 29, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Aug 29, 2022
Transactions value $
-$1,265,834
Form type
4
Date filed
8/31/2022, 05:45 PM
Previous filing
Aug 18, 2022
Next filing
Sep 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $405K +25K +8.61% $16.21 315K Aug 29, 2022 Direct
transaction CRSP Common Shares Sale -$269K -4.07K -1.29% $66.14 311K Aug 29, 2022 Direct F1, F2
transaction CRSP Common Shares Sale -$1.39M -20.8K -6.67% $66.98 290K Aug 29, 2022 Direct F1, F3
transaction CRSP Common Shares Sale -$11K -163 -0.06% $67.64 290K Aug 29, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -25K -30% $0.00 58.3K Aug 29, 2022 Common Shares 25K $16.21 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.55 to $66.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.55 to $67.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017.